{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:17:57Z","timestamp":1768281477905,"version":"3.49.0"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s11906-021-01151-8","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T14:03:05Z","timestamp":1620396185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Update on Treatment of Hypertension After Renal Transplantation"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-2346","authenticated-orcid":false,"given":"Christos","family":"Chatzikyrkou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland E.","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"issue":"Suppl s1","key":"1151_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ajt.15672","volume":"20","author":"A Hart","year":"2020","unstructured":"Hart A, Smith JM, Skeans MA, et al. OPTN\/SRTR 2018 annual data report: kidney. Am J Transplant. 2020;20(Suppl s1):20\u2013130.","journal-title":"Am J Transplant"},{"key":"1151_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2018.05.015","volume":"73","author":"DE Weiner","year":"2019","unstructured":"Weiner DE, Park M, Tighiouart H, Joseph AA, Carpenter MA, Goyal N, et al. Albuminuria and allograft failure, cardiovascular disease events, and all-cause death in stable kidney transplant recipients: a cohort analysis of the FAVORIT trial. Am J Kidney Dis. 2019;73:51\u201361.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/TP.0b013e3182a688e5","volume":"96","author":"A Faravardeh","year":"2013","unstructured":"Faravardeh A, Eickhoff M, Jackson S, Spong R, Kukla A, Issa N, et al. Predictors of graft failure and death in elderly kidney transplant recipients. Transplantation. 2013;96:1089\u201396.","journal-title":"Transplantation"},{"key":"1151_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/01.TP.0000437672.78716.28","volume":"97","author":"G Opelz","year":"2014","unstructured":"Opelz G, D\u00f6hler B. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation. 2014;97:310\u20135.","journal-title":"Transplantation"},{"key":"1151_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1681\/ASN.2014080834","volume":"26","author":"MR Weir","year":"2015","unstructured":"Weir MR, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, et al. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015;26:1248\u201360.","journal-title":"J Am Soc Nephrol"},{"key":"1151_CR6","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/ndt\/gfx283","volume":"32","author":"JM Halimi","year":"2017","unstructured":"Halimi JM, Persu A, Sarafidis PA, Burnier M, Abramowicz D, Sautenet B, et al. Optimizing hypertension management in renal transplantation: a call to action. Nephrol Dial Transplant. 2017;32:1959\u201362.","journal-title":"Nephrol Dial Transplant"},{"key":"1151_CR7","doi-asserted-by":"publisher","first-page":"Svii","DOI":"10.1053\/j.ajkd.2015.12.014","volume":"67","author":"R Saran","year":"2016","unstructured":"Saran R, Li Y, Robinson B, et al. US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67:Svii S1-305.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR8","doi-asserted-by":"publisher","first-page":"E438","DOI":"10.1111\/j.1399-0012.2012.01676.x","volume":"26","author":"MA Carpenter","year":"2012","unstructured":"Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. Clin Transpl. 2012;26:E438\u201346.","journal-title":"Clin Transpl"},{"key":"1151_CR9","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1097\/HJH.0b013e32834bd1e7","volume":"29","author":"C Chatzikyrkou","year":"2011","unstructured":"\u2022 Chatzikyrkou C, Menne J, Gwinner W, et al. Pathogenesis and management of hypertension after kidney transplantation. J Hypertens. 2011;29:2283\u201394 This was our first review on this topic published more than ten years ago.","journal-title":"J Hypertens"},{"key":"1151_CR10","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/nm.2497","volume":"17","author":"EJ Hoorn","year":"2011","unstructured":"\u2022 Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17:1304\u20139 An important paper elucidating the mechanisms of calcineurin inhibitor induced hypertension.","journal-title":"Nat Med"},{"key":"1151_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2016.12.017","volume":"69","author":"AD Moes","year":"2017","unstructured":"\u2022 Moes AD, Hesselink DA, van den Meiracker AH, et al. Chlorthalidone versus amlodipine for fypertension in kidney transplant recipients treated with tacrolimus: a randomized crossover trial. Am J Kidney Dis. 2017;69:796\u2013804 The basic science results of the previous study were here corroborated in the clinical setting.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ki.2013.278","volume":"85","author":"N Issa","year":"2014","unstructured":"Issa N, Ortiz F, Reule SA, Kukla A, Kasiske BL, Mauer M, et al. The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure. Kidney Int. 2014;85:404\u201315.","journal-title":"Kidney Int"},{"key":"1151_CR13","doi-asserted-by":"publisher","first-page":"F529","DOI":"10.1152\/ajprenal.00025.2019","volume":"317","author":"LA Mortensen","year":"2019","unstructured":"Mortensen LA, Bistrup C, Stubbe J, Carlstr\u00f6m M, Checa A, Wheelock CE, et al. Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients. Am J Physiol Ren Physiol. 2019;317:F529\u2013f539.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1151_CR14","doi-asserted-by":"publisher","first-page":"9762","DOI":"10.1038\/s41598-019-46114-x","volume":"9","author":"JJ Kovarik","year":"2019","unstructured":"Kovarik JJ, Kaltenecker CC, Kopecky C, Domenig O, Antlanger M, Werzowa J, et al. Intrarenal renin-angiotensin-system dysregulation after kidney transplantation. Sci Rep. 2019;9:9762.","journal-title":"Sci Rep"},{"key":"1151_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/ng.3667","volume":"48","author":"GB Ehret","year":"2016","unstructured":"Ehret GB, Ferreira T, Chasman DI, et al. The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nat Genet. 2016;48:1171\u201384.","journal-title":"Nat Genet"},{"key":"1151_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.105.063636","volume":"51","author":"TM Coffman","year":"2008","unstructured":"Coffman TM, Crowley SD. Kidney in hypertension: guyton redux. Hypertension. 2008;51:811\u20136.","journal-title":"Hypertension"},{"key":"1151_CR17","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887\u201398.","journal-title":"N Engl J Med"},{"key":"1151_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311:507\u201320.","journal-title":"Jama"},{"key":"1151_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(12)61343-9","volume":"381","author":"MA Weber","year":"2013","unstructured":"Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013;381:537\u201345.","journal-title":"Lancet"},{"key":"1151_CR20","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"\u2022\u2022 Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953\u20132041 The actual guidelines on hypertension treatment in the general and high risk populations. Due to the lack of evidence in transplantation, hypertension treatment goals proposed by these guidelines have also been adopted for renal transplant recipients.","journal-title":"J Hypertens"},{"key":"1151_CR21","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","volume":"315","author":"JD Williamson","year":"2016","unstructured":"Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 years: A Randomized Clinical Trial. Jama. 2016;315:2673\u201382.","journal-title":"Jama"},{"key":"1151_CR22","first-page":"e426","volume":"138","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey de Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e426\u201383.","journal-title":"Circulation"},{"key":"1151_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","volume":"62","author":"SJ Taler","year":"2013","unstructured":"Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62:201\u201313.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR24","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"KDOQI Clinical Practice Guideline for Diabetes and CKD","year":"2012","unstructured":"KDOQI Clinical Practice Guideline for Diabetes and CKD. 2012 update. Am J Kidney Dis. 2012;60:850\u201386.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2337\/ds17-0085","volume":"31","author":"P Passarella","year":"2018","unstructured":"Passarella P, Kiseleva TA, Valeeva FV, Gosmanov AR. Hypertension management in diabetes: 2018 update. Diabetes Spectr. 2018;31:218\u201324.","journal-title":"Diabetes Spectr"},{"key":"1151_CR26","doi-asserted-by":"crossref","unstructured":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S125-s150.","DOI":"10.2337\/dc21-S010"},{"key":"1151_CR27","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334\u201357.","journal-title":"Hypertension"},{"issue":"Suppl 3","key":"1151_CR28","first-page":"S1","volume":"9","author":"KDIGO","year":"2009","unstructured":"KDIGO. clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1\u2013155.","journal-title":"Am J Transplant"},{"key":"1151_CR29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"KDIGO 2021","year":"2021","unstructured":"\u2022\u2022 KDIGO 2021. clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:S1\u2013s87 The latest guideleines on management of BP in patients with chronic kidney disease. Again, due to the scarcity of data and the inconclusive evidence in transplantation, BP goals proposed by these guidelines are also adopted for the treatment of posttransplant hypertension.","journal-title":"Kidney Int"},{"key":"1151_CR30","doi-asserted-by":"publisher","first-page":"448.e1","DOI":"10.1016\/j.ahj.2006.03.004","volume":"152","author":"AG Bostom","year":"2006","unstructured":"Bostom AG, Carpenter MA, Kusek JW, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J. 2006;152:448.e1\u20137.","journal-title":"Am Heart J"},{"key":"1151_CR31","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1111\/j.1600-6143.2012.04101.x","volume":"12","author":"DE Weiner","year":"2012","unstructured":"Weiner DE, Carpenter MA, Levey AS, Ivanova A, Cole EH, Hunsicker L, et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant. 2012;12:2437\u201345.","journal-title":"Am J Transplant"},{"key":"1151_CR32","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1681\/ASN.2013040435","volume":"25","author":"MA Carpenter","year":"2014","unstructured":"\u2022\u2022 Carpenter MA, John A, Weir MR, et al. BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. J Am Soc Nephrol. 2014;25:1554\u201362 The only study, which was a post hoc analysis, associating systolic and diastolic BP levels with cardiovascular outcome in kidney transplant recipients.","journal-title":"J Am Soc Nephrol"},{"key":"1151_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1053\/j.ajkd.2016.01.019","volume":"68","author":"T Dad","year":"2016","unstructured":"Dad T, Tighiouart H, Joseph A, Bostom A, Carpenter M, Hunsicker L, et al. Aspirin use and incident cardiovascular disease, kidney failure, and death in stable kidney transplant recipients: a post hoc analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial. Am J Kidney Dis. 2016;68:277\u201386.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR34","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1111\/ajt.14258","volume":"17","author":"MC Foster","year":"2017","unstructured":"Foster MC, Weiner DE, Bostom AG, Carpenter MA, Inker LA, Jarolim P, et al. Filtration markers, cardiovascular disease, mortality, and kidney outcomes in stable kidney transplant recipients: The FAVORIT Trial. Am J Transplant. 2017;17:2390\u20139.","journal-title":"Am J Transplant"},{"key":"1151_CR35","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1111\/ajt.14284","volume":"17","author":"M Park","year":"2017","unstructured":"Park M, Katz R, Shlipak MG, Weiner D, Tracy R, Jotwani V, et al. Urinary markers of fibrosis and risk of cardiovascular events and death in kidney transplant recipients: the FAVORIT trial. Am J Transplant. 2017;17:2640\u20139.","journal-title":"Am J Transplant"},{"key":"1151_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.amjmed.2017.08.038","volume":"131","author":"LA Weinrauch","year":"2018","unstructured":"Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn PV, Liu J, et al. Infection and malignancy outweigh cardiovascular mortality in kidney transplant recipients: post hoc analysis of the FAVORIT trial. Am J Med. 2018;131:165\u201372.","journal-title":"Am J Med"},{"key":"1151_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000491025","volume":"48","author":"A Bostom","year":"2018","unstructured":"Bostom A, Pasch A, Madsen T, Roberts MB, Franceschini N, Steubl D, et al. Serum calcification propensity and fetuin-A: biomarkers of cardiovascular disease in kidney transplant recipients. Am J Nephrol. 2018;48:21\u201331.","journal-title":"Am J Nephrol"},{"key":"1151_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000489095","volume":"47","author":"A Bostom","year":"2018","unstructured":"Bostom A, Steubl D, Garimella PS, Franceschini N, Roberts MB, Pasch A, et al. Serum uromodulin: a biomarker of long-term kidney allograft failure. Am J Nephrol. 2018;47:275\u201382.","journal-title":"Am J Nephrol"},{"key":"1151_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.ajkd.2017.04.014","volume":"70","author":"B Merhi","year":"2017","unstructured":"Merhi B, Shireman T, Carpenter MA, Kusek JW, Jacques P, Pfeffer M, et al. Serum phosphorus and risk of cardiovascular disease, all-cause mortality, or graft failure in kidney transplant recipients: an ancillary study of the FAVORIT trial cohort. Am J Kidney Dis. 2017;70:377\u201385.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR40","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1681\/ASN.2015030292","volume":"27","author":"N Bansal","year":"2016","unstructured":"Bansal N, Carpenter MA, Weiner DE, Levey AS, Pfeffer M, Kusek JW, et al. Urine injury biomarkers and risk of adverse outcomes in recipients of prevalent kidney transplants: the Folic Acid for Vascular Outcome Reduction in Transplantation trial. J Am Soc Nephrol. 2016;27:2109\u201321.","journal-title":"J Am Soc Nephrol"},{"key":"1151_CR41","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","volume":"389","author":"M B\u00f6hm","year":"2017","unstructured":"B\u00f6hm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226\u201337.","journal-title":"Lancet"},{"key":"1151_CR42","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1093\/eurheartj\/ehy287","volume":"39","author":"M B\u00f6hm","year":"2018","unstructured":"B\u00f6hm M, Schumacher H, Teo KK, Lonn E, Mahfoud F, Mann JFE, et al. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Eur Heart J. 2018;39:3105\u201314.","journal-title":"Eur Heart J"},{"key":"1151_CR43","doi-asserted-by":"crossref","first-page":"e13329","DOI":"10.1111\/petr.13329","volume":"23","author":"T Seeman","year":"2019","unstructured":"Seeman T, Vondr\u00e1k K, Du\u0161ek J. Effects of the strict control of blood pressure in pediatric renal transplant recipients-ESCORT trial. Pediatr Transplant. 2019;23:e13329.","journal-title":"Pediatr Transplant"},{"key":"1151_CR44","doi-asserted-by":"publisher","first-page":"I319","DOI":"10.1161\/CIRCULATIONAHA.105.001503","volume":"114","author":"D Ramzy","year":"2006","unstructured":"Ramzy D, Rao V, Tumiati LC, Xu N, Sheshgiri R, Miriuka S, et al. Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway. Circulation. 2006;114:I319\u201326.","journal-title":"Circulation"},{"key":"1151_CR45","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/j.1432-2277.2006.00372.x","volume":"19","author":"M Silverborn","year":"2006","unstructured":"Silverborn M, Ambring A, Nilsson F, Friberg P, Jeppsson A. Vascular resistance and endothelial function in cyclosporine-treated lung transplant recipients. Transpl Int. 2006;19:974\u201381.","journal-title":"Transpl Int"},{"key":"1151_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/ki.2009.418","volume":"77","author":"K Madsen","year":"2010","unstructured":"Madsen K, Friis UG, Gooch JL, Hansen PB, Holmgaard L, Sk\u00f8tt O, et al. Inhibition of calcineurin phosphatase promotes exocytosis of renin from juxtaglomerular cells. Kidney Int. 2010;77:110\u20137.","journal-title":"Kidney Int"},{"key":"1151_CR47","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1097\/HJH.0b013e32833c20eb","volume":"28","author":"IH Klein","year":"2010","unstructured":"Klein IH, Abrahams AC, van Ede T, et al. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity. J Hypertens. 2010;28:1928\u201334.","journal-title":"J Hypertens"},{"key":"1151_CR48","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1161\/HYPERTENSIONAHA.110.162917","volume":"57","author":"VL Chiasson","year":"2011","unstructured":"Chiasson VL, Talreja D, Young KJ, Chatterjee P, Banes-Berceli AK, Mitchell BM. FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension. Hypertension. 2011;57:1167\u201375.","journal-title":"Hypertension"},{"key":"1151_CR49","doi-asserted-by":"crossref","unstructured":"\u2022 Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010:Cd007893. An important metaanalysis showing the association between dosage and BP increase. In this paper the effect of various daily dosages of cyclosporin on BP were quantified.","DOI":"10.1002\/14651858.CD007893.pub2"},{"key":"1151_CR50","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1681\/ASN.2007080911","volume":"19","author":"JE Goodwin","year":"2008","unstructured":"\u2022 Goodwin JE, Zhang J, Geller DS. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol. 2008;19:1291\u20139 An important paper showing an interesting alternative but also equally detrimental mechanism of glucocorticoid-induced hypertension.","journal-title":"J Am Soc Nephrol"},{"key":"1151_CR51","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0272-6386(99)70414-2","volume":"33","author":"DL Veenstra","year":"1999","unstructured":"Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999;33:829\u201339.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR52","first-page":"Cd010699","volume":"2014","author":"P Masson","year":"2014","unstructured":"Masson P, Henderson L, Chapman JR, et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014;2014:Cd010699.","journal-title":"Cochrane Database Syst Rev"},{"key":"1151_CR53","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1161\/CIRCULATIONAHA.109.930446","volume":"122","author":"A Vinh","year":"2010","unstructured":"\u2022 Vinh A, Chen W, Blinder Y, et al. Inhibition and genetic ablation of the B7\/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation. 2010;122:2529\u201337 An interesting paper implicating immunologic mechanisms in the pathogenesis of hypertension that could be modulated by belatacept.","journal-title":"Circulation"},{"key":"1151_CR54","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00228-018-2512-7","volume":"74","author":"W Saengram","year":"2018","unstructured":"Saengram W, Vadcharavivad S, Poolsup N, Chancharoenthana W. Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74:1249\u201360.","journal-title":"Eur J Clin Pharmacol"},{"key":"1151_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/TP.0b013e3182958552","volume":"96","author":"JS Mourer","year":"2013","unstructured":"Mourer JS, de Koning EJ, van Zwet EW, et al. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients. Transplantation. 2013;96:49\u201357.","journal-title":"Transplantation"},{"key":"1151_CR56","doi-asserted-by":"crossref","unstructured":"Lopez-Soler RI, Chan R, Martinolich J, Park L, Ata A, Chandolias N, et al. Early steroid withdrawal results in improved patient and graft survival and lower risk of post-transplant cardiovascular risk profiles: a single-center 10-year experience. Clin Transpl. 2017;31.","DOI":"10.1111\/ctr.12878"},{"key":"1151_CR57","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1111\/ajt.14897","volume":"18","author":"C Sommerer","year":"2018","unstructured":"Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, et al. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. Am J Transplant. 2018;18:2965\u201376.","journal-title":"Am J Transplant"},{"key":"1151_CR58","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/ajt.12952","volume":"15","author":"K Budde","year":"2015","unstructured":"Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant. 2015;15:119\u201328.","journal-title":"Am J Transplant"},{"key":"1151_CR59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12882-018-1031-1","volume":"19","author":"C Sommerer","year":"2018","unstructured":"Sommerer C, Witzke O, Lehner F, et al. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrol. 2018;19:237.","journal-title":"BMC Nephrol"},{"key":"1151_CR60","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.4103\/1319-2442.248292","volume":"29","author":"A Azarfar","year":"2018","unstructured":"Azarfar A, Ravanshad Y, Mehrad-Majd H, Esmaeeli M, Aval SB, Emadzadeh M, et al. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: an updated systematic review and meta-analysis. Saudi J Kidney Dis Transpl. 2018;29:1376\u201385.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"1151_CR61","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","volume":"388","author":"O Thomusch","year":"2016","unstructured":"\u2022 Thomusch O, Wiesener M, Opgenoorth M, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet. 2016;388:3006\u201316 A recent randomised controlled study of early steroid withdrawal after renal transplantaion.","journal-title":"Lancet"},{"key":"1151_CR62","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1681\/ASN.2018010009","volume":"29","author":"J Pascual","year":"2018","unstructured":"Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29:1979\u201391.","journal-title":"J Am Soc Nephrol"},{"key":"1151_CR63","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/ajt.15480","volume":"19","author":"SP Berger","year":"2019","unstructured":"Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, et al. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant. 2019;19:3018\u201334.","journal-title":"Am J Transplant"},{"key":"1151_CR64","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","volume":"103","author":"H Tedesco-Silva","year":"2019","unstructured":"Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim DY, et al. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. 2019;103:1953\u201363.","journal-title":"Transplantation"},{"key":"1151_CR65","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1053\/j.ajkd.2020.07.018","volume":"77","author":"GL Hundemer","year":"2021","unstructured":"\u2022 Hundemer GL, Knoll GA, Petrcich W, et al. Kidney, cardiac, and safety outcomes associated with \u03b1-blockers in patients with CKD: a population-based cohort study. Am J Kidney Dis. 2021;77:178\u2013189.e1 An interesting registry analysis showing positive effects of an neglected antihypertensive drug class in patients with chronic kidney disease.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR66","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1016\/j.transproceed.2011.04.011","volume":"43","author":"S Wagner","year":"2011","unstructured":"Wagner S, Greco F, Doehn C, Hoda MR, Girndt M, Jocham D, et al. Laparoscopic versus open bilateral nephrectomy in transplant recipients with medication-resistant hypertension: final results of a multicenter study with 15 years of follow-up. Transplant Proc. 2011;43:2557\u201361.","journal-title":"Transplant Proc"},{"key":"1151_CR67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98\u2013105.","journal-title":"Heart"},{"key":"1151_CR68","doi-asserted-by":"publisher","first-page":"e13803","DOI":"10.1111\/ctr.13803","volume":"34","author":"FM Koraishy","year":"2020","unstructured":"Koraishy FM, Yamout H, Naik AS, et al. Impacts of center and clinical factors in antihypertensive medication use after kidney transplantation. Clin Transpl. 2020;34:e13803.","journal-title":"Clin Transpl"},{"key":"1151_CR69","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145\u201353.","journal-title":"N Engl J Med"},{"key":"1151_CR70","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782\u20138.","journal-title":"Lancet"},{"key":"1151_CR71","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1681\/ASN.2018040443","volume":"29","author":"V Saglimbene","year":"2018","unstructured":"Saglimbene V, Palmer SC, Ruospo M, Natale P, Maione A, Nicolucci A, et al. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): a randomized, controlled trial. J Am Soc Nephrol. 2018;29:2890\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"1151_CR72","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"P Ruggenenti","year":"1997","unstructured":"Ruggenenti P, Perna A, Negri M, Matalone M. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349:1857\u201363.","journal-title":"Lancet"},{"key":"1151_CR73","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"1151_CR74","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","volume":"174","author":"TW Hsu","year":"2014","unstructured":"Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med. 2014;174:347\u201354.","journal-title":"JAMA Intern Med"},{"key":"1151_CR75","doi-asserted-by":"crossref","unstructured":"Bolignano D, Palmer SC, Navaneethan SD, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014:Cd007004.","DOI":"10.1002\/14651858.CD007004.pub3"},{"key":"1151_CR76","doi-asserted-by":"publisher","first-page":"e0127320","DOI":"10.1371\/journal.pone.0127320","volume":"10","author":"Z Huang","year":"2015","unstructured":"Huang Z, Wu B, Tao J, Han Z, Yang X, Zhang L, et al. Association between angiotensin I-Converting enzyme insertion\/deletion polymorphism and prognosis of kidney transplantation: a meta-analysis. PLoS One. 2015;10:e0127320.","journal-title":"PLoS One"},{"key":"1151_CR77","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1681\/ASN.2012080777","volume":"24","author":"HN Ibrahim","year":"2013","unstructured":"\u2022 Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol. 2013;24:320\u20137 An interesting study testing the effects of RAS blockers on allograft histology and function.","journal-title":"J Am Soc Nephrol"},{"key":"1151_CR78","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/TP.0b013e3182827a43","volume":"95","author":"E Paoletti","year":"2013","unstructured":"Paoletti E, Bellino D, Marsano L, Cassottana P, Rolla D, Ratto E. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation. 2013;95:889\u201395.","journal-title":"Transplantation"},{"key":"1151_CR79","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.ajkd.2007.04.013","volume":"50","author":"E Paoletti","year":"2007","unstructured":"Paoletti E, Cassottana P, Amidone M, Gherzi M, Rolla D, Cannella G. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. Am J Kidney Dis. 2007;50:133\u201342.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR80","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10157-019-01827-1","volume":"24","author":"A Tsuchimoto","year":"2020","unstructured":"Tsuchimoto A, Masutani K, Ueki K, et al. Effect of renin-angiotensin system blockade on graft survival and cardiovascular disease in kidney transplant recipients: retrospective multicenter study in Japan. Clin Exp Nephrol. 2020;24:369\u201378.","journal-title":"Clin Exp Nephrol"},{"key":"1151_CR81","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/08037051.2016.1182856","volume":"26","author":"C Chatzikyrkou","year":"2017","unstructured":"Chatzikyrkou C, Eichler J, Karch A, Clajus C, Scurt FG, Ramackers W, et al. Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation. Blood Press. 2017;26:30\u20138.","journal-title":"Blood Press"},{"key":"1151_CR82","doi-asserted-by":"publisher","first-page":"e000091","DOI":"10.1161\/JAHA.112.000091","volume":"2","author":"W Aftab","year":"2013","unstructured":"Aftab W, Varadarajan P, Rasool S, et al. Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients. J Am Heart Assoc. 2013;2:e000091.","journal-title":"J Am Heart Assoc"},{"key":"1151_CR83","first-page":"613","volume":"67","author":"Z Heleniak","year":"2020","unstructured":"Heleniak Z, Illersperger S, Brakemeier S, Bach P, D\u0119bska-\u015alizie\u0144 A, Budde K, et al. The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients - a cross-sectional prospective observational clinical study. Acta Biochim Pol. 2020;67:613\u201322.","journal-title":"Acta Biochim Pol"},{"key":"1151_CR84","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.transproceed.2018.03.027","volume":"50","author":"Z Heleniak","year":"2018","unstructured":"Heleniak Z, Ku\u017amiuk-Glembin I, Adrych D, Garnier H, Wi\u015bniewski J, Rutkowski P, et al. Management of renin-angiotensin-aldosterone system blockade in kidney transplant recipients. Transplant Proc. 2018;50:1842\u20136.","journal-title":"Transplant Proc"},{"key":"1151_CR85","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/ndt\/gfr276","volume":"27","author":"D Hern\u00e1ndez","year":"2012","unstructured":"Hern\u00e1ndez D, Muriel A, Abraira V, P\u00e9rez G, Porrini E, Marrero D, et al. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study. Nephrol Dial Transplant. 2012;27:417\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"1151_CR86","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S2213-8587(15)00368-X","volume":"4","author":"GA Knoll","year":"2016","unstructured":"\u2022\u2022 Knoll GA, Fergusson D, Chass\u00e9 M, et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:318\u201326 The only non-industry sponsored randomized controlled study that failed to prove the presumed superiority of RAS blockers in renal transplantation.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1151_CR87","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ndt\/gfp581","volume":"25","author":"T Philipp","year":"2010","unstructured":"\u2022 Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant. 2010;25:967\u201376 Another improtant randomized controlled study dealing with RAS blockers in kidney transplantation. This study had to be terminated prematurely due to futility.","journal-title":"Nephrol Dial Transplant"},{"key":"1151_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000357205","volume":"39","author":"DJ Salzberg","year":"2014","unstructured":"Salzberg DJ, Karadsheh FF, Haririan A, Reddivari V, Weir MR. Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade. Am J Nephrol. 2014;39:1\u20137.","journal-title":"Am J Nephrol"},{"key":"1151_CR89","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1097\/TP.0000000000000938","volume":"100","author":"JI Shin","year":"2016","unstructured":"Shin JI, Palta M, Djamali A, Kaufman DB, Astor BC. The association between renin-angiotensin system blockade and long-term outcomes in renal transplant recipients: the Wisconsin Allograft Recipient Database (WisARD). Transplantation. 2016;100:1541\u20139.","journal-title":"Transplantation"},{"key":"1151_CR90","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","volume":"69","author":"S Hiremath","year":"2017","unstructured":"\u2022 Hiremath S, Fergusson DA, Fergusson N, et al. Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2017;69:78\u201386 The newest and largest meta-analysis on the effects of RAS blockers in kidney transplant recipients.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kjms.2017.07.007","volume":"34","author":"YM Jiang","year":"2018","unstructured":"Jiang YM, Song TR, Qiu Y, Liu JP, Wang XD, Huang ZL, et al. Effect of renin-angiotensin system inhibitors on survival in kidney transplant recipients: a systematic review and meta-analysis. Kaohsiung J Med Sci. 2018;34:1\u201313.","journal-title":"Kaohsiung J Med Sci"},{"key":"1151_CR92","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"\u2022\u2022 Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368 A very important study showing the efficacy of mineralcorticoid receptor antagonists in the treatment of resistant hypertension. The results of this study were impressive and the subsequent guidelines adopted this drug class and integrated it in the treatment algorithm of hypertnesion.","journal-title":"Lancet"},{"key":"1151_CR93","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"1151_CR94","first-page":"197","volume":"1","author":"M Papadimitriou","year":"1983","unstructured":"\u2022 Papadimitriou M, Vyzantiadis A, Milionis A, et al. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Support Syst. 1983;1:197\u2013205 The first study using an aldosterone antagonist in chronic kidney disease and transplantation.","journal-title":"Life Support Syst"},{"key":"1151_CR95","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/ndt\/gfy065","volume":"33","author":"S Girerd","year":"2018","unstructured":"Girerd S, Jaisser F. Mineralocorticoid receptor antagonists in kidney transplantation: time to consider? Nephrol Dial Transplant. 2018;33:2080\u201391.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"1151_CR96","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/dom.13983","volume":"22","author":"O Al Dhaybi","year":"2020","unstructured":"Al Dhaybi O, Bakris GL. Non-steroidal mineralocorticoid antagonists: prospects for renoprotection in diabetic kidney disease. Diabetes Obes Metab. 2020;22(Suppl 1):69\u201376.","journal-title":"Diabetes Obes Metab"},{"key":"1151_CR97","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","volume":"50","author":"LM Ruilope","year":"2019","unstructured":"Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, et al. Design and baseline characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial. Am J Nephrol. 2019;50:345\u201356.","journal-title":"Am J Nephrol"},{"key":"1151_CR98","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1056\/NEJMoa035717","volume":"352","author":"D Dragun","year":"2005","unstructured":"Dragun D, M\u00fcller DN, Br\u00e4sen JH, Fritsche L, Nieminen-Kelh\u00e4 M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352:558\u201369.","journal-title":"N Engl J Med"},{"key":"1151_CR99","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/00007890-200504270-00020","volume":"79","author":"U Fuchs","year":"2005","unstructured":"Fuchs U, Zittermann A, Berthold HK, Tenderich G, Deyerling KW, Minami K, et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation. 2005;79:981\u20133.","journal-title":"Transplantation"},{"key":"1151_CR100","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ckj\/sfu001","volume":"7","author":"C Gharbi","year":"2014","unstructured":"Gharbi C, Gueutin V, Izzedine H. Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor\/proliferation signal inhibitors (mTOR-I\/PSIs). Clin Kidney J. 2014;7:115\u201320.","journal-title":"Clin Kidney J"},{"key":"1151_CR101","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/TP.0b013e3181a9e960","volume":"88","author":"NB Cross","year":"2009","unstructured":"Cross NB, Webster AC, Masson P, O'Connell PJ, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation. 2009;88:7\u201318.","journal-title":"Transplantation"},{"key":"1151_CR102","doi-asserted-by":"publisher","first-page":"32s","DOI":"10.1016\/0002-9343(91)90483-E","volume":"90","author":"MR Weir","year":"1991","unstructured":"Weir MR. Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. Am J Med. 1991;90:32s\u20136s.","journal-title":"Am J Med"},{"key":"1151_CR103","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1177\/1060028014550644","volume":"48","author":"E Bernard","year":"2014","unstructured":"Bernard E, Goutelle S, Bertrand Y, Bleyzac N. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Ann Pharmacother. 2014;48:1580\u20134.","journal-title":"Ann Pharmacother"},{"key":"1151_CR104","doi-asserted-by":"publisher","first-page":"e13633","DOI":"10.1111\/ctr.13633","volume":"33","author":"RR Jensen","year":"2019","unstructured":"Jensen RR, Healy RM, Ford CD, et al. Amlodipine and calcineurin inhibitor-induced nephrotoxicity following allogeneic hematopoietic stem cell transplant. Clin Transpl. 2019;33:e13633.","journal-title":"Clin Transpl"},{"key":"1151_CR105","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.healun.2020.01.1342","volume":"39","author":"M Hornum","year":"2020","unstructured":"Hornum M, Iversen M, Oturai P, Andersen MJ, Zemtsovski M, Bredahl P, et al. Felodipine and renal function in lung transplantation: a randomized placebo-controlled trial. J Heart Lung Transplant. 2020;39:541\u201350.","journal-title":"J Heart Lung Transplant"},{"key":"1151_CR106","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/11593800-000000000-00000","volume":"11","author":"J Cai","year":"2011","unstructured":"Cai J, Huang Z, Yang G, Cheng K, Ye Q, Ming Y, et al. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy. Am J Cardiovasc Drugs. 2011;11:401\u20139.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1151_CR107","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/ndt\/gfz092","volume":"35","author":"A Pisano","year":"2020","unstructured":"\u2022\u2022 Pisano A, Bolignano D, Mallamaci F, et al. Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2020;35:878\u201387 An important recent review comparing different antihypertensive drug classes in kidney transplantation.","journal-title":"Nephrol Dial Transplant"},{"key":"1151_CR108","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","volume":"78","author":"SA Pedersen","year":"2018","unstructured":"Pedersen SA, Gaist D, Schmidt SAJ, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78:673\u2013681.e9.","journal-title":"J Am Acad Dermatol"},{"key":"1151_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.12.003","volume":"122","author":"S Gandini","year":"2018","unstructured":"Gandini S, Palli D, Spadola G, Bendinelli B, Cocorocchio E, Stanganelli I, et al. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2018;122:1\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1151_CR110","unstructured":"\u2022 Emma Coplant (Oxford G). Antihypertensive drugs and cancer risk: an IPD meta-analysis in the BPLTTC. ESH Congress 2020, 2020;Late-Breaking Science in Hypertension. An important analysis showing that the use of any antihypertensive drug class did not have any significant effect on the risk of cancer."},{"key":"1151_CR111","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1111\/ajt.14382","volume":"17","author":"A Mittal","year":"2017","unstructured":"\u2022\u2022 Mittal A, Colegio OR. Skin cancers in organ transplant recipients. Am J Transplant. 2017;17:2509\u201330 An important review on skin cancers in Transplantation.","journal-title":"Am J Transplant"},{"key":"1151_CR112","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.2215\/CJN.02560220","volume":"15","author":"T Letellier","year":"2020","unstructured":"Letellier T, Leborgne F, Kerleau C, Gaultier A, Dantal J, Ville S, et al. Association between use of hydrochlorothiazide and risk of keratinocyte cancers in kidney transplant recipients. Clin J Am Soc Nephrol. 2020;15:1804\u201313.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1151_CR113","unstructured":"In Brief: Hydrochlorothiazide and skin cancer. Med Lett Drugs Ther 2020;62:177."},{"key":"1151_CR114","first-page":"19","volume":"19","author":"GA Hofmann","year":"2021","unstructured":"Hofmann GA, Weber B. Drug-induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences. J Dtsch Dermatol Ges. 2021;19:19\u201329.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1151_CR115","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1526924816664084","volume":"26","author":"K Asai","year":"2016","unstructured":"Asai K, Kobayashi T, Miyata H, Tanaka Y, Okada Y, Sakai K, et al. The short-term impact of dietary counseling on sodium intake and blood pressure in renal allograft recipients. Prog Transplant. 2016;26:365\u201371.","journal-title":"Prog Transplant"},{"key":"1151_CR116","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1053\/j.ajkd.2015.11.026","volume":"67","author":"LV de Vries","year":"2016","unstructured":"de Vries LV, Dobrowolski LC, van den Bosch JJ, et al. Effects of dietary sodium restriction in kidney transplant recipients treated with renin-angiotensin-aldosterone system blockade: a randomized clinical trial. Am J Kidney Dis. 2016;67:936\u201344.","journal-title":"Am J Kidney Dis"},{"key":"1151_CR117","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12916-015-0340-5","volume":"13","author":"JA Lafranca","year":"2015","unstructured":"Lafranca JA, JN IJ, Betjes MG, et al. Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. BMC Med. 2015;13:111.","journal-title":"BMC Med"},{"key":"1151_CR118","doi-asserted-by":"publisher","first-page":"e0191009","DOI":"10.1371\/journal.pone.0191009","volume":"13","author":"DC Yazbek","year":"2018","unstructured":"Yazbek DC, Carvalho AB, Barros CS, Medina Pestana JO, Rochitte CE, dos Santos Filho RD, et al. Is there relationship between epicardial fat and cardiovascular parameters in incident kidney transplant patients? A post-hoc analysis PLoS One. 2018;13:e0191009.","journal-title":"A post-hoc analysis PLoS One"},{"key":"1151_CR119","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40697-015-0059-4","volume":"2","author":"G Chan","year":"2015","unstructured":"Chan G, Garneau P, Hajjar R. The impact and treatment of obesity in kidney transplant candidates and recipients. Can J Kidney Health Dis. 2015;2:26.","journal-title":"Can J Kidney Health Dis"},{"key":"1151_CR120","doi-asserted-by":"crossref","unstructured":"Totti V, Fernhall B, Di Michele R, et al. Longitudinal analysis of cardiovascular risk factors in active and sedentary kidney transplant recipients. Medicina (Kaunas). 2020;56.","DOI":"10.3390\/medicina56040183"},{"key":"1151_CR121","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/14740338.2020.1732921","volume":"19","author":"C Ponticelli","year":"2020","unstructured":"Ponticelli C, Arnaboldi L, Moroni G, Corsini A. Treatment of dyslipidemia in kidney transplantation. Expert Opin Drug Saf. 2020;19:257\u201367.","journal-title":"Expert Opin Drug Saf"},{"key":"1151_CR122","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/07853890.2016.1243803","volume":"49","author":"LH Qu","year":"2017","unstructured":"Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Ann Med. 2017;49:142\u201356.","journal-title":"Ann Med"},{"key":"1151_CR123","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000490261","volume":"140","author":"M Gritter","year":"2018","unstructured":"Gritter M, Vogt L, Yeung SMH, Wouda RD, Ramakers CRB, de Borst MH, et al. Rationale and design of a randomized placebo-controlled clinical trial assessing the renoprotective effects of potassium supplementation in chronic kidney disease. Nephron. 2018;140:48\u201357.","journal-title":"Nephron"},{"key":"1151_CR124","doi-asserted-by":"publisher","first-page":"F1090","DOI":"10.1152\/ajprenal.00343.2020","volume":"319","author":"EC Mannon","year":"2020","unstructured":"Mannon EC, O'Connor PM. Alkali supplementation as a therapeutic in chronic kidney disease: what mediates protection? Am J Physiol Ren Physiol. 2020;319:F1090\u2013f1104.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1151_CR125","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ajt.15590","volume":"20","author":"J Boucquemont","year":"2020","unstructured":"Boucquemont J, Pai ALH, Dharnidharka VR, Hebert D, Zelikovsky N, Amaral S, et al. Association between day of the week and medication adherence among adolescent and young adult kidney transplant recipients. Am J Transplant. 2020;20:274\u201381.","journal-title":"Am J Transplant"},{"key":"1151_CR126","doi-asserted-by":"publisher","first-page":"e13682","DOI":"10.1111\/ctr.13682","volume":"33","author":"M Gomis-Pastor","year":"2019","unstructured":"Gomis-Pastor M, Roig Mingell E, Mirabet Perez S, et al. Multimorbidity and medication complexity: New challenges in heart transplantation. Clin Transpl. 2019;33:e13682.","journal-title":"Clin Transpl"},{"key":"1151_CR127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224595","volume":"14","author":"A Han","year":"2019","unstructured":"Han A, Min SI, Ahn S, Min SK, Hong HJ, Han N, et al. Mobile medication manager application to improve adherence with immunosuppressive therapy in renal transplant recipients: a randomized controlled trial. PLoS One. 2019;14:e0224595.","journal-title":"PLoS One"},{"key":"1151_CR128","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/ajhp\/zxz115","volume":"76","author":"DJ Taber","year":"2019","unstructured":"Taber DJ, Pilch NA, McGillicuddy JW, et al. Using informatics and mobile health to improve medication safety monitoring in kidney transplant recipients. Am J Health Syst Pharm. 2019;76:1143\u20139.","journal-title":"Am J Health Syst Pharm"},{"key":"1151_CR129","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0140-6736(85)90627-0","volume":"2","author":"JJ Curtis","year":"1985","unstructured":"Curtis JJ, Luke RG, Diethelm AG, Whelchel JD, Jones P. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet. 1985;2:739\u201342.","journal-title":"Lancet"},{"key":"1151_CR130","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(13)62192-3","volume":"383","author":"H Krum","year":"2014","unstructured":"Krum H, Schlaich MP, Sobotka PA, B\u00f6hm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622\u20139.","journal-title":"Lancet"},{"key":"1151_CR131","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393\u2013401.","journal-title":"N Engl J Med"},{"key":"1151_CR132","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/ndt\/gfv311","volume":"30","author":"S Schneider","year":"2015","unstructured":"Schneider S, Promny D, Sinnecker D, Byrne RA, M\u00fcller A, Dommasch M, et al. Impact of sympathetic renal denervation: a randomized study in patients after renal transplantation (ISAR-denerve). Nephrol Dial Transplant. 2015;30:1928\u201336.","journal-title":"Nephrol Dial Transplant"},{"key":"1151_CR133","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0003319710377076","volume":"62","author":"A Seratnahaei","year":"2011","unstructured":"Seratnahaei A, Shah A, Bodiwala K, Mukherjee D. Management of transplant renal artery stenosis. Angiology. 2011;62:219\u201324.","journal-title":"Angiology"},{"key":"1151_CR134","doi-asserted-by":"publisher","first-page":"e13217","DOI":"10.1111\/ctr.13217","volume":"32","author":"LX Chen","year":"2018","unstructured":"Chen LX, De Mattos A, Bang H, et al. Angioplasty vs stent in the treatment of transplant renal artery stenosis. Clin Transpl. 2018;32:e13217.","journal-title":"Clin Transpl"},{"key":"1151_CR135","first-page":"106","volume":"7","author":"NMP Maideen","year":"2019","unstructured":"Maideen NMP. Drug interactions of dihydropyridine calcium channel blockers (CCBs) involving CYP3A4 enzymes. Eur J Med. 2019;7:106\u201313.","journal-title":"Eur J Med"},{"key":"1151_CR136","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1161\/CIRCRESAHA.114.301809","volume":"114","author":"GA FitzGerald","year":"2014","unstructured":"FitzGerald GA. Testing cardiovascular drug safety and efficacy in randomized trials. Circ Res. 2014;114:1156\u201361.","journal-title":"Circ Res"},{"key":"1151_CR137","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/ajt.12050","volume":"13","author":"A Ibrahim","year":"2013","unstructured":"Ibrahim A, Garg AX, Knoll GA, Akbari A, White CA. Kidney function endpoints in kidney transplant trials: a struggle for power. Am J Transplant. 2013;13:707\u201313.","journal-title":"Am J Transplant"},{"key":"1151_CR138","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S2213-8587(15)00377-0","volume":"4","author":"MJ Brown","year":"2016","unstructured":"Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4:136\u201347.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1151_CR139","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/eurheartj\/ehz651","volume":"41","author":"G Mancia","year":"2020","unstructured":"Mancia G, Facchetti R, Cuspidi C, Bombelli M, Corrao G, Grassi G. Limited reproducibility of MUCH and WUCH: evidence from the ELSA study. Eur Heart J. 2020;41:1565\u201371.","journal-title":"Eur Heart J"},{"key":"1151_CR140","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jash.2015.04.001","volume":"9","author":"MH Lee","year":"2015","unstructured":"Lee MH, Ko KM, Ahn SW, Bae MN, Choi BS, Park CW, et al. The impact of kidney transplantation on 24-hour ambulatory blood pressure in end-stage renal disease patients. J Am Soc Hypertens. 2015;9:427\u201334.","journal-title":"J Am Soc Hypertens"},{"key":"1151_CR141","doi-asserted-by":"crossref","unstructured":"Pisano A, Mallamaci F, D'Arrigo G, et al. Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrol Dial Transplant 2021.","DOI":"10.1093\/ndt\/gfab076"},{"key":"1151_CR142","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1093\/eurheartj\/ehz754","volume":"41","author":"RC Hermida","year":"2020","unstructured":"Hermida RC, Crespo JJ, Dom\u00ednguez-Sardi\u00f1a M, Otero A, Moy\u00e1 A, R\u00edos MT, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020;41:4565\u201376.","journal-title":"Eur Heart J"},{"key":"1151_CR143","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1097\/HJH.0000000000002671","volume":"38","author":"R Kreutz","year":"2020","unstructured":"Kreutz R, Kjeldsen SE, Burnier M, Narkiewicz K, Oparil S, Mancia G. Disregard the reported data from the HYGIA project: blood pressure medication not to be routinely dosed at bedtime. J Hypertens. 2020;38:2144\u20135.","journal-title":"J Hypertens"},{"key":"1151_CR144","doi-asserted-by":"publisher","first-page":"i4098","DOI":"10.1136\/bmj.i4098","volume":"354","author":"SL Stevens","year":"2016","unstructured":"Stevens SL, Wood S, Koshiaris C, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. Bmj. 2016;354:i4098.","journal-title":"Bmj"},{"key":"1151_CR145","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jch.13304","volume":"20","author":"G Parati","year":"2018","unstructured":"Parati G, Stergiou GS, Dolan E, Bilo G. Blood pressure variability: clinical relevance and application. J Clin Hypertens (Greenwich). 2018;20:1133\u20137.","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-021-01151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-021-01151-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-021-01151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:11:41Z","timestamp":1699009901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-021-01151-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":145,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1007\/s11906-021-01151-8","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"26 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"25"}}